ACCELERO: Ph3 Study of Rilvegostomig in combo w/ Chemo in 1st Line met NSCLC PD-L1 (ARTEMIDE-Lung03)

Phase III Clinical Trial

A Phase III Randomized Double-Blind Multicenter Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03). (D702FC00001)

Indication: Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer
Trial Number: 06627647
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations